Abstract 114P
Background
PD-1 inhibitors plus chemotherapy have been the standard 1L treatment for metastatic G/GEJA, but its efficacy remain poor in patients (pts) with low PD-L1 expression. A phase III study has demonstrated that cadonilimab, a PD-1/CTLA-4 bispecific antibody, showed encouraging activity and manageable safety in previously untreated pts with metastatic G/GEJA, even those with PD-L1 CPS<5. Currently, cadonilimab combined with XELOX as 1L treatment for metastatic G/GEJA was approved by NMPA. Here, we presented the updated efficacy and safety of the combination for metastatic G/GEJA with PD-L1 CPS≤5 in a real-world setting.
Methods
Untreated pts with metastatic G/GEJA and PD-L1 CPS≤5 who has received cadonilimab combined with chemotherapy (SOX, XELOX or FOLFOX) were included in this real-world study. Baseline characteristics, treatment patterns, and clinical outcomes, including objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS) and treatment-related adverse events (TRAEs) were analyzed.
Results
As of August 24, 2024, 31 pts were enrolled. At baseline, median age was 56.0 years (range: 25-75), 67.7% were ECOG PS 1/2 and 48.4% were PD-L1 CPS<1. 4 pts underwent surgical treatment under the guidance of MDT, including 3 with PD-L1 CPS<1. All pts were evaluable for safety and efficacy. 17 reached PR and 14 were SD. Overall ORR was 54.8% and DCR was 100.0%. Median PFS (mPFS) was 7.38 months (mo) (95% Cl: 5.55-9.21) and median OS (mOS) was 14.26 mo (95% Cl: 11.08-17.44). In the PD-L1 CPS<1 group, the ORR was 53.3% (8/15) and DCR was 100.0% (15/15), mPFS was 9.25 mo (95% Cl: 0.00-20.09) and mOS was 14.26 mo (95% Cl: 7.78-20.74). Pts with liver metastasis (25.8%, 8/31) had a higher ORR (8 PR, 100%) compared to the overall ORR (54.8%). TRAEs were observed in 67.7% pts, including 9.7% grade 3 TRAEs (neutropenia 6.5%, thrombocytopenia 3.2% and diabetes 3.2%). There were no grade 4/5 toxicities.
Conclusions
Cadonilimab plus chemotherapy continued to show a promising efficacy with manageable safety in the 1L treatment of metastatic G/GEJA pts with PD-L1 CPS≤5, particularly a high ORR in pts with liver metastasis.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
43P - Machine learning radiomics based on CT to predict response to lenvatinib plus tislelizumab based therapy for unresectable hepatocellular carcinoma
Presenter: Gang Chen
Session: Poster Display session
Resources:
Abstract
44P - Machine learning-based prediction of survival in patients with metastatic renal cell carcinoma receiving first-line immunotherapy
Presenter: Ahmed Elgebaly
Session: Poster Display session
Resources:
Abstract
45P - Gut microbiome signatures for exploring the correlation between gut microbiome and immune therapy response using machine learning approach
Presenter: Han Li
Session: Poster Display session
Resources:
Abstract
46P - Abnormal gut microbiota may cause PD-1 inhibitor-related cardiotoxicity via suppressing regulatory T cells
Presenter: Zeeshan Afzal
Session: Poster Display session
Resources:
Abstract
47P - Correlation of clinical, genetic and transcriptomic traits with PD-L1 positivity in TNBC patients
Presenter: Anita Semertzidou
Session: Poster Display session
Resources:
Abstract
48P - The A2AR antagonist inupadenant promotes humoral responses in preclinical models
Presenter: Paola Tieppo
Session: Poster Display session
Resources:
Abstract
49P - Highly potent novel armoured IL13Ra2 CAR T cell targeting glioblastoma
Presenter: Maurizio Mangolini
Session: Poster Display session
Resources:
Abstract
50P - Phase I trial of P-MUC1C-ALLO1 allogeneic CAR-T cells in advanced epithelial malignancies
Presenter: David Oh
Session: Poster Display session
Resources:
Abstract
51P - Unlocking CAR-T cell potential: Lipid metabolites in overcoming exhaustion in ovarian cancer
Presenter: Xiangyu Chang
Session: Poster Display session
Resources:
Abstract
52P - Tumor-targeted cytokine release by genetically-engineered myeloid cells rescues CAR-T activity and engages endogenous T cells against high-grade glioma in mouse models
Presenter: Federico Rossari
Session: Poster Display session
Resources:
Abstract